Androgen Receptor Signaling in Prostate Cancer: New Twists for an Old Pathway

Feng, Junjie; Zheng, Shaojiang

doi:10.4172/2157-7536.s2-001

“…The AR homodimers translocate to the cell nucleus and bind androgen responsive genes (ARG) at specific palindromic DNA sequences known as androgen responsive elements (ARE) (Feng, Zheng, Wennuan, Isaacs, & Xu, 2011). Upon binding to ARE, AR dimers can act as a scaffold toward the recruitment of accessory proteins to assemble an active transcription complex (Feng et al, 2011;Heinlein & Chang, 2002;Roy, Lavrosky, & Song, 1999).…”

Section: Ar Signaling Finds Its Intracellularmentioning

confidence: 99%

Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer

Martin

¹

,

Kyprianou

²

2015

Advances in Cancer Research

View full text Add to dashboard Cite

“…The growth and progression of prostate cancer is stimulated by androgens [2]. Androgens are male sex steroid hormones that are responsible for the development of male characteristics.…”

Section: Introductionmentioning

confidence: 99%

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer

Arshad

¹

,

Datta

²

2016

Proceedings of the 7th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics

View full text Add to dashboard Cite

Background: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical castration. CRPC is a complex, multifaceted and heterogeneous malady with limited standard treatment options. Results: The growth and progression of prostate cancer is a complicated process that involves multiple pathways. The signaling network comprising the integral constituents of the signature pathways involved in the development and progression of prostate cancer is modeled as a combinatorial circuit. The failures in the gene regulatory network that lead to cancer are abstracted as faults in the equivalent circuit and the Boolean circuit model is then used to design therapies tailored to counteract the effect of each molecular abnormality and to propose potentially efficacious combinatorial therapy regimens. Furthermore, stochastic computational modeling is utilized to identify potentially vulnerable components in the network that may serve as viable candidates for drug development. Conclusion:The results presented herein can aid in the design of scientifically well-grounded targeted therapies that can be employed for the treatment of prostate cancer patients.

show abstract

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer

Arshad

¹

,

Datta

²

2017

View full text Add to dashboard Cite

Background: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical castration. CRPC is a complex, multifaceted and heterogeneous malady with limited standard treatment options. Results: The growth and progression of prostate cancer is a complicated process that involves multiple pathways. The signaling network comprising the integral constituents of the signature pathways involved in the development and progression of prostate cancer is modeled as a combinatorial circuit. The failures in the gene regulatory network that lead to cancer are abstracted as faults in the equivalent circuit and the Boolean circuit model is then used to design therapies tailored to counteract the effect of each molecular abnormality and to propose potentially efficacious combinatorial therapy regimens. Furthermore, stochastic computational modeling is utilized to identify potentially vulnerable components in the network that may serve as viable candidates for drug development. Conclusion:The results presented herein can aid in the design of scientifically well-grounded targeted therapies that can be employed for the treatment of prostate cancer patients.

show abstract

Androgen Receptor Signaling in Prostate Cancer: New Twists for an Old Pathway

Cited by 4 publications

References 108 publications

Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer

Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer

Contact Info

Product

Resources

About